MLLAB.PA Media Lab (EURONEXT) +14.48% pre-market Mar 2026: model implies 60.21% upside

MLLAB.PA stock is trading up 14.48% pre-market at €3.32 on EURONEXT on Mar 2026 after a sharp intraday move that leaves the company among top gainers in Europe. The jump follows thin trading (volume 2.00, avg 180.00) and a tight free float, pushing a small-cap market cap of €7,868,400.00 into focus. Investors are noting Media Lab S.p.A.’s niche position in dental IT, a PE 18.44 and an unusually high dividend yield of 9.34%, all of which inform near-term trading and analyst model updates

Pre-market performance: MLLAB.PA stock price and volume

MLLAB.PA stock opened and sits at €3.32, up €0.42 or 14.48% versus the previous close of €2.90. Trading is extremely light with reported volume 2.00 versus average volume 180.00, creating volatility risk despite the outsized percentage move. The share set shows a year high €4.30 and year low €1.90, with 50-day average €3.39 and 200-day average €3.36, highlighting a tight trading range ahead of broader sector flows

Drivers and context behind the move for MLLAB.PA stock

There is no scheduled earnings announcement on file, so the pre-market rise looks driven by technical factors and low liquidity rather than a public earnings shock. Media Lab S.p.A. has 2,370,000.00 shares outstanding and a small free float, which amplifies price moves when buy interest appears. The company’s niche in dental implant planning software, steady margins and a €0.31 dividend per share (yield 9.34%) make it attractive to yield-seeking traders in a low-liquidity name

Fundamentals and valuation: what MLLAB.PA stock looks like

Media Lab reports EPS €0.18 and a trailing PE 18.44, with revenue per share €0.77 and book value per share €0.58, indicating modest scale but profitable operations. Key valuation multiples show price/sales 4.32 and price/book 5.74, while return on equity is 35.12%, reflecting strong profitability on a small base. Balance-sheet strengths include cash per share €0.21 and very low debt (debt/equity 0.02), but high price-based ratios mean expectations are elevated

Technical setup and short-term signals for MLLAB.PA stock

Technically, MLLAB.PA stock is oversold-to-recover with RSI 28.02 and Bollinger middle band €3.30, upper €3.67 and lower €2.94, so the current price sits near the 20-day mean. ADX 39.51 shows a strong trend, while MACD is flat (MACD 0.02, signal 0.02) implying momentum is fragile. Immediate support is €3.30 and resistance sits at the band upper €3.67 and the year high €4.30; thin volume makes breakouts noisy

Meyka AI grade and forecasts for MLLAB.PA stock

Meyka AI rates MLLAB.PA with a score out of 100: 67.76 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, industry metrics, financial growth, key ratios, forecasts and analyst signals. Meyka AI’s forecast model projects monthly €3.67, quarterly €3.90 and yearly €5.32, which compared to the current price €3.32 implies +60.21% upside to the 12-month model target. Forecasts are model-based projections and not guarantees

Risks and opportunities for investors in MLLAB.PA stock

Key risks: very low liquidity (volume 2.00, avg 180.00) and small market cap €7,868,400.00 can magnify downside; high price-to-book (5.74) and heavy reliance on a narrow dental IT market raise execution risk. Opportunities: strong margins (net margin 23.18%), low leverage (debt/equity 0.02) and a high dividend yield 9.34% that can attract income buyers if payouts are sustained. Watch receivables cycle (DSO 160.01 days) and sector flows in Healthcare, which is underperforming year-to-date, for catalysts

Final Thoughts

MLLAB.PA stock stands out as a top pre-market gainer on Mar 2026, trading €3.32 after a 14.48% lift on very light volume. Fundamentals show profitable operations (EPS €0.18, ROE 35.12%) and a generous dividend (€0.31, yield 9.34%), but valuation multiples (P/S 4.32, P/B 5.74) assume continued growth. Technically the name is recovering from oversold readings (RSI 28.02) but faces resistance near €3.67 and the year high €4.30. Meyka AI’s forecast model projects a 12-month level of €5.32, implying +60.21% upside versus today’s price €3.32, though forecasts are model-based and not guarantees. Given the B / HOLD Meyka grade, traders should prioritise liquidity and event-risk management: consider shorter-term entries near €3.30–€3.40, and treat the yearly €5.32 projection as a longer-term scenario contingent on revenue traction and dividend sustainability. For live quote pages see our Meyka stock page and Media Lab site for company filings and updates

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.